Home » Posts tagged with » Nivolumab
OncoSec Medical begins phase 2 OMS-104 melanoma trial with TAVO, OPDIVO combo

OncoSec Medical begins phase 2 OMS-104 melanoma trial with TAVO, OPDIVO combo

OncoSec Medical has dosed the first patient in the OMS-104 phase 2 clinical trial, which is evaluating TAVO (tavokinogene telseplasmid) in combination with OPDIVO (nivolumab) as a neoadjuvant therapy for melanoma. TAVO is OncoSec Medical’s intratumoral DNA plasmid-based interleukin-12 (IL-12) therapy, which is intended to be administered using its gene delivery platform (gene electrotransfer). On […]

BMS gets Opdivo EC approval for second-line treatment of ESCC

Opdivo EC approval : Bristol Myers Squibb (BMS) has secured approval from the European Commission (EC) for its immunotherapy Opdivo (nivolumab) as a second-line treatment for unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) in adults. The approval of the programmed death-1 (PD-1) immune checkpoint inhibitor is for patients who were previously subjected […]

Continue reading …
BMS’ Opdivo plus Yervoy combo gets EC approval for metastatic NSCLC

Bristol Myers Squibb (BMS) has secured approval from the European Commission (EC) for Opdivo (nivolumab) plus Yervoy (ipilimumab) for the first-line treatment of metastatic non-small cell lung cancer (NSCLC). The approval is for the Opdivo/Yervoy combination to be used with two cycles of platinum-based chemotherapy in adult patients, whose tumors have no sensitizing epidermal growth […]

Continue reading …
FDA approves BMS’ Opdivo, Yervoy combo for malignant pleural mesothelioma

Bristol Myers Squibb (BMS) has secured approval for Opdivo (nivolumab) and Yervoy (ipilimumab) combination from the US Food and Drug Administration (FDA) for the first-line treatment of unresectable malignant pleural mesothelioma (MPM) in adults. The approval is for Opdivo 360 mg every three weeks with 1 mg/kg every six weeks (injections for intravenous use) of […]

Continue reading …
FDA approves Opdivo + Yervoy for HCC previously treated with sorafenib

Bristol Myers Squibb has secured approval for the combination of Opdivo (nivolumab) 1 mg/kg and Yervoy (ipilimumab) 3 mg/kg from the US Food and Drug Administration (FDA) for the treatment of hepatocellular carcinoma (HCC) in patients who were previously treated with sorafenib. Approval for the indication has been issued under accelerated approval on the basis […]

Continue reading …
BMS’ Opdivo flops in CheckMate -331 trial in small cell lung cancer

Bristol-Myers Squibb (BMS) cancer drug Opdivo (nivolumab) failed to meet the primary endpoint of the phase 3 CheckMate -331 trial in small cell lung cancer patients whose condition relapsed after platinum-based chemotherapy treatment. Opdivo could not significantly improve overall survival in the patients in comparison to current standard of care chemotherapy of topotecan or amrubicin […]

Continue reading …
BMS, Compugen to trial COM701 Opdivo combo in advanced solid tumors

US biopharma company Bristol-Myers Squibb (BMS) has entered into a clinical collaboration with Compugen to evaluate the combination of its cancer drug Opdivo (nivolumab) with the Israeli genomics-based drug and diagnostic discovery company’s COM701 in advanced solid tumors. COM701 is being investigated by Compugen as an anti-PVRIG antibody while the cancer drug Opdivo is a […]

Continue reading …